Matrix-m
Matrix-m has been studied in 1 paper since 2022: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Apr 20, 2022: “Precision Vaccine Adjuvants for Older Adults: A Scoping Review”.
1 paper studies itUpdated
At a glance
3 trials, none about aging.
Cells, worms or flies, mice and humans: nothing yet.
- 3 trials, none about aging
- 1 of 3 trials sponsored by its developers
Who is developing matrix-m?
2 companies: Sanofi and Novavax.
Trial sponsors
Company1 trialPhase 46,500 people
Company1 trialPhase 4669 people
National Institute of Allergy and Infectious Diseases
1 trialPhase 1/2220 people
Latest
Clinical Infectious Diseases
Precision Vaccine Adjuvants for Older Adults: A Scoping Review
Systematic reviewInterventions